China: Food and Drugs Law

Subscribe

Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.

China Compliance Update: Life Sciences — Summer 2025

This Advisory summarizes developments in the compliance environment for life sciences companies in China in the first half of 2025, following significant developments from 2024.

China Healthcare

AP

Arnold & Porter

Growth and Opportunities in China's Medical Device Market.

Overview of the development, segmentation, driving forces, and emerging opportunities within China's medical device market.

China Healthcare

A

Acclime

试管婴儿辅助生殖行业法律问题探究

近期关于试管婴儿代孕、代为供卵取卵以及同性之间试管婴儿抚养权归属等问题媒体新闻报道越来越多

China Healthcare

AB

AnJie Broad Law Firm

China Advances Pharmaceutical Data Protection Regime With New Draft Measures

On March 19, 2025, China's National Medical Products Administration (NMPA) released the Draft Measures for the Protection of Drug Trial Data...

China Healthcare

AO

A&O Shearman

China Introduces A New Regulatory Data Protection And Exclusivity Mechanism

China Healthcare

AP

Arnold & Porter

Interpretation Of The Anti-Monopoly Guidelines For Pharmaceutical Sector: Key Risk Considerations

China Healthcare

AB

AnJie Broad Law Firm

Six Key Insights Into China Biotech's NewCo Model

China Healthcare

HK

Han Kun Law Offices

揭秘中国创新药企NewCo模式实战中的"六脉神剑"

China Healthcare

HK

Han Kun Law Offices

CN 2025 Drafts On Clinical Trial Data Exclusivity

China Healthcare

TM

Toby Mak

《关于药品领域的反垄断指南》解读：药企反垄断风险"划重点"

China Healthcare

AB

AnJie Broad Law Firm

China On The Move: Lessons From China's 2024 National Negotiation Of Drug Prices

China Healthcare

GT

Greenberg Traurig, LLP

China Life Sciences: 2024 Year In Review

China Healthcare

AP

Arnold & Porter

Chinese Regulators Publish Final Anti-Corruption Guidelines For The Healthcare Industry

China Healthcare

AP

Arnold & Porter

China Announces Major Policy Incentives For Life Sciences Companies

China Healthcare

RG

Ropes & Gray LLP

Six Key Insights Into China Biotech's NewCo Model

China Healthcare

HK

Han Kun Law Offices

Opportunities And Challenges Of Brazil-China Trade Under The Impact Of US Tariffs

Worldwide International

AB

AnJie Broad Law Firm

AFD China Newsletter - June, 2025

AC

AFD China

国际制裁措施对于合同履行的影响及应对 - 不可抗力篇

China Commercial

JT

Jincheng Tongda & Neal

Growth and Opportunities in China's Medical Device Market.

China Healthcare

A

Acclime

Food and Drugs Law

澳门特区专利药品及植物药剂产品保护补充证明书制度解析

我国澳门特别行政区依托...

CP

CCPIT Patent & Trademark Law Office

中国创新药械全球崛起法律保障系列文章之一：创新药研发企业临床试验数据对外跨境传输的监管要点

得益于药品上市许可持有人制度确立、药品审评审批制度改革、专利链接制度...

AB

AnJie Broad Law Firm

China Advances Pharmaceutical Data Protection Regime With New Draft Measures

On March 19, 2025, China's National Medical Products Administration (NMPA) released the Draft Measures for the Protection of Drug Trial Data...

China Healthcare

AO

A&O Shearman

马库什化合物专利申请中，这4个缺陷一定要规避！

K

Kangxin

China Introduces A New Regulatory Data Protection And Exclusivity Mechanism

China Healthcare

AP

Arnold & Porter

Interpretation Of The Anti-Monopoly Guidelines For Pharmaceutical Sector: Key Risk Considerations

China Healthcare

AB

AnJie Broad Law Firm

Six Key Insights Into China Biotech's NewCo Model

China Healthcare

HK

Han Kun Law Offices

Safeguards Of Dapagliflozin's Half Billion USD Sales In China: AstraZeneca

R

Rouse

CN 2025 Drafts On Clinical Trial Data Exclusivity

China Healthcare

TM

Toby Mak

See more

Life Sciences, Biotechnology & Nanotechnology

Growth and Opportunities in China's Medical Device Market.

Overview of the development, segmentation, driving forces, and emerging opportunities within China's medical device market.

China Healthcare

A

Acclime

Six Key Insights Into China Biotech's NewCo Model

In the age of globalization, Chinese pharmaceutical companies are at the forefront of innovation and collaboration, seizing unprecedented development opportunities.

China Healthcare

HK

Han Kun Law Offices

揭秘中国创新药企NewCo模式实战中的"六脉神剑"

在全球化背景之下，中国医药企业正站在创新与合作的新风口，迎接前所未有的发展契机。与此同时，海外投资者与医药企业亦在敏锐捕捉投$

China Healthcare

HK

Han Kun Law Offices

Safeguards Of Dapagliflozin's Half Billion USD Sales In China: AstraZeneca

R

Rouse

CN 2025 Drafts On Clinical Trial Data Exclusivity

China Healthcare

TM

Toby Mak

Application Of Bioisosterism In The Judgment Of Inventiveness

AC

AFD China

China Life Sciences: 2024 Year In Review

China Healthcare

AP

Arnold & Porter

Chinese Regulators Publish Final Anti-Corruption Guidelines For The Healthcare Industry

China Healthcare

AP

Arnold & Porter

医药企业申请商标的注意事项

CP

CCPIT Patent & Trademark Law Office

See more

Healthcare

China Compliance Update: Life Sciences — Summer 2025

This Advisory summarizes developments in the compliance environment for life sciences companies in China in the first half of 2025, following significant developments from 2024.

China Healthcare

AP

Arnold & Porter

Growth and Opportunities in China's Medical Device Market.

Overview of the development, segmentation, driving forces, and emerging opportunities within China's medical device market.

China Healthcare

A

Acclime

中国创新药械全球崛起法律保障系列文章之一：创新药研发企业临床试验数据对外跨境传输的监管要点

得益于药品上市许可持有人制度确立、药品审评审批制度改革、专利链接制度...

AB

AnJie Broad Law Firm

试管婴儿辅助生殖行业法律问题探究

China Healthcare

AB

AnJie Broad Law Firm

China Advances Pharmaceutical Data Protection Regime With New Draft Measures

China Healthcare

AO

A&O Shearman

里程碑式判决：经营者集中行政诉讼"第一案"代理有感

China Anti-trust

AB

AnJie Broad Law Firm

Safeguards Of Dapagliflozin's Half Billion USD Sales In China: AstraZeneca

R

Rouse

China Newsletter | Q4 2024/Issue No. 62

China International

GT

Greenberg Traurig, LLP

China Unveils New Anti-Monopoly Guidelines For The Pharmaceutical Sector

China Anti-trust

JD

Jones Day

See more

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More